A clinical imaging study using [18F]F-AraG PET to visualize Tumor infiltrating T-cell Activation in Non-small cell lung cancer
- Conditions
- lung cancerlung carcinoma1003866610010613
- Registration Number
- NL-OMON50793
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 10
1. Histologically confirmed NSCLC, a histological biopsy is mandatory.
2. Patients that are resectable upfront as per multidisciplinary tumor board
evaluation.
3. Be willing and able to provide written informed consent for the trial.
4. Be above 18 years of age on day of signing informed consent.
5. Have a performance status of 0-1 on the ECOG Performance Scale at screening.
1. Subjects with a condition requiring systemic treatment with either
corticosteroids (> 10 mg daily prednisone equivalent) or other
immunosuppressive medications within 14 days of screening. Inhaled or topical
steroids, and adrenal replacement steroid >10 mg daily prednisone
equivalent, are permitted in the absence of active autoimmune disease.
2. Psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
3. Patient is pregnant or breastfeeding or expecting to conceive within the
projected duration of the trial, starting with the screening visit through 12
weeks after the last [18F]F-AraG PET scan.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method